# 2025-16266: LUMISIGHT Gets FDA Nod for Extended Patent Protection

2025-16266, Determination of Regulatory Review Period for Purposes of Patent Extension; LUMISIGHT, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-08-26 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-16266
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-16266
- Title: Determination of Regulatory Review Period for Purposes of Patent Extension; LUMISIGHT
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 41567
- Published: 2025-08-26
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

LUMISIGHT Gets FDA Nod for Extended Patent Protection

## Summary

The FDA has officially set the review period for LUMISIGHT, a human drug product, so its patent can be extended. This means the company behind LUMISIGHT gets more time to protect their invention and potentially make more money. Anyone involved in drug patents or development should watch this timeline closely for opportunities or changes.

## Abstract

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LUMISIGHT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-16266 on federalregister.gov](https://www.federalregister.gov/documents/2025/08/26/2025-16266/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lumisight)
- [2025-16266 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-08-26/pdf/2025-16266.pdf)

## Related
- [Previous: 2025-16265, Determination of Regulatory Review Period for Purposes of Patent Extension; IQI…](https://policyrisk.com/federal-register/2025-16265)
- [Next: 2025-16267, Determination of Regulatory Review Period for Purposes of Patent Extension; NEM…](https://policyrisk.com/federal-register/2025-16267)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-16266 (as of 2026-06-08).
